MADRID, Spain and CAMBRIDGE, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reports financial results for the fourth quarter of 2019 and provides an update on recent developments. “Oryzon continued to make strong clinical progress in the fourth quarter,” said Dr. Carlos Buesa, Oryzon’s Chief Executive O
February 24, 2020
· 9 min read